Advertisement
New RAC verteporfin audits are being challenged
A result of excessive vitreous base shaving?
Four therapies from which to choose.
Ocriplasmin: two decades of commitment to a concept.
What clinical and economic evidence exists to support ILM peeling?
Recurrence of hemorrhage after vitrectomy can be a troublesome complication.
Our coverage of the 2012 Retinal Physician Symposium continues.
FDA approves Lucentis for DME; Could an eyedrop treat wet AMD; LCA-causing gene is Isolated; Five-year follow-up on Lucentis for RVO; and more
An ocular oncologist offers his clinical opinions.
To peel or not to peel — That is the question